Abstract: Prostate cancer is a kind of male malignancy. Recently, a large number of studies have reported many potential biomarkers for the diagnosis and prognosis of prostate cancer. In this literature review, we have collected a number of potential biomarkers for prostate cancer reported in the last 5 years. Among them, some are undergoing Phase III clinical trials, and others have been approved by the US Food and Drug Administration. However, most are still in the period of basic research. The review will contribute to future research to find the biomarkers to guide clinicians to make personalized treatment decisions for each prostate cancer patient. Keywords: lncRNAs, microRNAs, fusion gene, TMPRSS2-ERG, methylation
Introduction
The MALAT-1 score was tested in a discovery phase and a multicenter validation phase. According to the decision curve analysis, using a probability threshold of 25%, the MALAT-1 model would prevent 30.2%-46.5% of unnecessary biopsies in PSA 4-10 ng/mL cohorts, without missing any high-grade cancers were still in the laboratory research stage. We classified these molecules and looked forward for providing the researchers with a general overview of the PCa biomarkers.
PSA
PSA was the most widely used biomarker in clinical practice since the mid-80s. It was used as an adjunctive test to early screen PCa, to assess patients' response to treatments, and to predict recurrence in the whole stage of PCa progression. In 1986, the Food and Drug Administration (FDA) approved that PSA was used for dynamic monitoring recurrence after initial treatment. 5 Since then, the PCa cases in America doubled from 55/100,000 men to 110/100,000. In 1994, FDA authorized that PSA was used in the clinic for early diagnosis of PCa. 6 However, until today we still do not know how many PSA screening has reduced PCa cases and costs. The European Randomized Study of Screening for Prostate Cancer has found that clinicians must screen 1,410 men and treat 48 potential patients to prevent one person from dying of PCa. 5 In 2012, the US Preventative Services Task Force recommended that PSA testing was only used in high-risk populations. 7 Several derivatives of PSA, including serum free PSA and PSA velocity, and the isoforms of PSA, including p2PSA, have been considered as potential biomarkers to improve the diagnostic accuracy by combining with PSA. 5 However, these auxiliary biomarkers are not PCa specific, which drastically reduces their application value. At present, PSA test is more commonly used as a screening method in clinical practice, and further diagnostic tests should be taken for 
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Long noncoding RNA
A lot of long noncoding RNAs (lncRNA) were identified to be associated with tumor, which might play the important roles in carcinogenesis and PCa progression. LncRNAs not only promoted cancer cells proliferation, invasion, and metastasis, but also had the potential value to become biomarkers for predicting various tumors. Several kinds of PCa-related lncRNAs are summarized as follows.
Prostate cancer antigen 3 (PCA3) was overexpressed as a second-line biomarker in PCa tissues compared with control samples. Mechanistic studies illustrated that it might regulate androgen receptor (AR) signaling to improve PCa cell survival. In addition, PCA3 level was not increased in prostatic inflammatory or hyperplasia, and its level was not associated with prostatic volume. 8 Moreover, PCA3 expression level was correlated with biopsy outcome and PCa progression (eg, tumor grade and Gleason score). 8 In 2012, FDA approved that the PCA3 expression level was detected as a diagnostic test for PCa in the cases with a prior negative biopsy. 9 Patients with PCA3 score 25 were 4.56-fold more likely to have a negative biopsy than men with its score 25. 9 In 2017, PCA3 performance was compared with the European Randomized Study of Screening for Prostate Cancer risk calculator model 3 in an opportunistic screening. 10 Eight hundred thirty-eight men with a normal DRE result and PSA 3 ng/mL had the PCA3 test done. In PCA3 positive (n=301) and PCA3 negative (n=256) groups, 40.9% and 14.7% PCa were identified, respectively (P0.001). 10 The false-negative cases for high-grade PCa would be reduced by 37.1%. 10 Although the PCA3 screening might have potential as a second-line test used in men with high PSA levels, the prognostic value of PCA3 score remained controversial because the cutoff value was debated. Leyten et al found that sensitivity increased from 0.68 to 0.83 when the cutoff value reduced from 35 to 25, while specificity decreased from 0.58 to 0.51. Besides, PCAT14 (prostate cancer-associated transcript 14) was a kind of PCa-related suppressive lncRNA, which was transcriptionally regulated by AR. PCAT14 was found to be downregulated in aggressive PCa, and the loss of PCAT14 might predict PCa recurrence based on the large-scale RNA-sequencing data. 11 MALAT-1 (metastasis-associated lung adenocarcinoma transcript 1) had a higher area under the curve (AUC) compared to PSA level on the basis of a multicenter clinical trial to predict the risk of PCa before biopsy. The results showed that MALAT-1 might reduce 30.2%-46.5% of unnecessary biopsies with PSA 4-10 ng/mL using the cutoff value of 25%. 12 In addition, PCA18 (prostate cancer antigen 18) was also confirmed to be PCa-specific upregulated in PCa tissues compared with benign prostatic hyperplasia (BPH) samples (P0.001).
13 PVT1 (plasmacytoma variant translocation 1) exon 9 was associated with aggressive PCa.
14 SChLAP1 (second chromosome locus associated with prostate-1) was upregulated in a subtype of PCa and associated with lethal PCa. The overexpression of SChLAP1 could independently predict biochemical recurrence of PCa after radical prostatectomy (RP). Knockdown of SChLAP1 induced apoptosis and inhibited cell invasion and metastasis. 15, 16 Among various lncRNAs, PCA3 has the most promising clinical application value and can be used as a second-line biomarker to predict the results of biopsy. Other lncRNAs also have great application prospects, and most of them are still in the research stage at present.
MicroRNAs
MicroRNA (miRNA) is a kind of small noncoding RNA with 20-24 nucleotides in length, which post-transcriptionally regulates target gene expressions by binding to the 3′-UTRs of complementary mRNAs. Deregulated miRNAs were reported to play dual roles in multiple cellular pathways in a variety of solid tumors.
A study found that the expression level of miR-34a was decreased in clinical PCa samples and was related with the progression and poor prognosis of PCa, and miR-34a might regulate BCL-2, SNCA, and SCL7A5. 17 miR-1 was significantly downregulated in recurrent PCa compared to nonrecurrent PCa samples (P0.001). 18 There were 78 patients in the analysis, including 27 recurrent PCa and 51 nonrecurrent PCa. The Cox proportional hazards analysis revealed that miR-1 might be the independent prognostic factor for PCa recurrence (HR: 1.86, 95% CI: 1.21-2.94; P=0.011). The AUC value of miR-1 was 0.885, the sensitivity was 0.863, and the specificity was 0.889 (P0.001). 18 Another biochemical recurrence predictor, miR-129, was also downregulated in peripheral blood mononuclear cells (PBMC) isolated from 98 PCa patients compared to 56 matched controls (P0.05). 19 The expression level of miR-129 was significantly related with many PCa clinical characteristics: PSA level (P=0.002), tumor stage (P=0.011), Gleason score (P=0.005), lymph node metastasis (P=0.002), and biochemical recurrence (P=0.001), and so on.
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The expression levels of miR-21 were upregulated in PBMC from PCa patients compared to benign control group (P0.05). 20 In the study, 92 PCa patients, 85 BPH cases, and 97 healthy controls were involved. miR-21 expression level was significantly related with Gleason score, tumor stage, bone metastasis, and recurrence (P0.05). Receiver operating characteristic analysis uncovered that the AUC value of miR-21 was 0.974 with 95% CI 0.956-0.993. The sensitivity and specificity were 93.5% and 92.9%, respectively. The results illustrated that the miR-21 expression level had the potential to be an independent biomarker for predicting the prognosis of PCa (P0.05). 20 Egidi et al also monitored the serum level of miR-21 in 38 patients with PCa before and after RP. MiR-21 was found to be significantly increased on the fifth day after surgery, and then gradually returned to the preoperative level. These findings suggested that miR-21 might be involved in postoperative inflammatory processes. 21 Cochetti studied the serum level of miRNAs of PCa patients, and they found that seven miRNAs (let-7c, let-7e, let-7i, miR-26a-5p, miR-26b-5p, miR-18b-5p, and miR-25-3p) could distinguish PCa from BPH. 22 In addition, Egidi 23 and Guelfi 24 detected miRNAs in the urine sediments, and found the potential application value of miR-191 23 and let-7 family 24 as noninvasive biomarkers in the diagnosis of PCa.
Our group conducted a meta-analysis and a review on differentially expressed miRNAs in PCa. 25, 26 In the metaanalysis, we integrated the expression profile data of miRNAs and evaluated the value of miRNAs as biomarkers of PCa. 25 In the review, we also listed a variety of miRNAs that could identify PCa and BPH/normal.
26
TMPRSS2-eRG
In 2005, Tomlins et al first reported the gene fused between ERG (ETS (erythroblast transformation-specific)-related gene) and TMPRSS2 (transmembrane protease, serine 2) genes.
27 TMPRSS2-ERG was the PCa-specific fusion gene, and there was ARE in the TMPRSS2 promoter, which might be activated by androgen, while the oncogene ERG was a kind of transcription factor as one member of ETS family. The fusion frequency of TMPRSS2-ERG was ~50% in Caucasian American cohorts, 31% in African American cohorts, and 18.5% in Asian cohorts. The fusion gene could regulate proliferation, differentiation, cell cycle, and so on, and played an important role in the development of PCa. TMPRSS2-ERG fusion gene was thought to be the driving factor for PCa.
In 2011, Tomlins et al found that the expression level of TMPRSS2-ERG fusion in the urine samples of biopsy and prostatectomy was associated with PCa volume and Gleason score. But TMPRSS2-ERG had not been found to be associated with long-term patient outcomes: biochemical recurrence and PCa-specific mortality. Using urinary TMPRSS2-ERG as a single marker, the test had low sensitivity but high specificity, which was very high up to 93.2%. 9 In the cohort studies, TMPRSS2-ERG fusion detection prior to biopsy was reported to avoid 35%-47% of biopsies, while to delay the diagnosis of high-grade PCa in only 1.0%-2.3%. 9 Even so, TMPRSS2-ERG fusion-based screening was limited due to its low sensitivity. So, a method to improve the discriminatory ability of TMPRSS2-ERG fusion was proposed by combining with the other urinary markers: PSA or PCA3. 28 Recently, a commercial kit might provide 90% specificity and 80% sensitivity for PCa, combined detection of serum PSA, urinary PCA3, and TMPRSS2-ERG. 28 In 2018, our group conducted a meta-analysis on the predictive potential of TMPRSS2-ERG fusion gene. The results showed that the expression level of TMPRSS2-ERG was associated with PCa tumor stage, Gleason score, and metastasis. But it was not related with biochemical recurrence, mortality, and tumor volume. At the same time, the data showed that deletion fusion was significantly correlated with the malignant degree of PCa. 29 
Oncogene
In 2014, Antonarakis et al evaluated the expression level of androgen receptor splice variant-7 (AR-V7) in circulating tumor cells (CTCs) from metastatic castrate-resistant prostate cancer (mCRPC) patients treated by enzalutamide or abiraterone. The results demonstrated that the AR-V7 expression was associated with PCa shorter survival. 30 In 2016, Scher et al also verified that patients with AR-V7-positive CTCs had shorter radiographic progression-free survival and shorter overall survival (OS) than those with AR-V7-negative in 161 progressive mCRPC patients (HR: 0.24, 95% CI: 0.10-0.57; P=0.035). 31 
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Tumor suppressor gene
Phosphatase and tensin homolog (PTEN) is a tumor suppressor gene to regulate proliferation, cell cycle, and apoptosis by a lot of downstream target genes. Among them, phosphatidylinositol-3,4,5 phosphate (PIP3) is dephosphorylated by PTEN to become phosphatidylinositol-4,5 phosphate (PIP2), then the membrane lipid is activated and released Akt kinase. In 2015, Shah et al reported that PTEN loss was associated with high Gleason score (P0.01) in 194 multiple-foci PCa cohort. 65 PTEN loss was found in 36% (69) of patients. Moreover, 39% of tumor samples with hemizygous PTEN deletion was reported by Yoshimoto, while homozygous deletion was found in 5% of cases, and these samples with homozygous deletion were more likely to occur biochemical recurrence (P=0.005). Clusterin (CLU) is a stress-induced cytoprotective chaperone, associated with tumor stage, metastasis, and treatment resistance for some cancers. In a Phase II clinical study on custirsen, a CLU antisense oligonucleotide, custirsen as a second-line drug was evaluated in patients with mCRPC. The results showed that the lower serum CLU level indicated the longer survival period in mCRPC patients during the treatment with custirsen. 66 Moreover, in a Phase III trial, the low expression of AZGP1 (zinc-alpha 2-glycoprotein) might independently predict the shorter recurrence-free survival (HR, 1.9; 95% CI: 1.1-3.3; P=0.02).
67
PSF1 (Partner of SLD51) is a kind of DNA replication factor, which was verified that its transcriptional activity was related with Gleason score (P0.0001), PSA level (P=0.0028), and tumor stage (P=0.0005) in 120 PCa biopsy samples. Noteworthily, PSF1 was also associated with OS (HR: 5.5, 95% CI: 2.17-15.8; P=0.003) and prognosis (HR: 3.7, 95% CI: 1.28-13.43; P=0.0143) in 99 PCa patients. 68 Eotaxin-1 (CCL11) is an immunomodulatory chemokine attracting eosinophils. In the study using serum from 140 patients with elevated PSA levels and 20 controls, it was found that serum CCL11 levels were decreased in PCa group compared to the control (P=0.006), and eotaxin-1 might be a potential biomarker to distinguish PCa patients from benign prostate cases. 69 In addition, other tumor suppressors were also confirmed to be downregulated in PCa compared to that in the healthy controls, including SOX2 (the SRY (sex-determining region Y)-box 2), 70 75 and SFRP1 (secreted frizzled-related protein-1) (P=0.016). 76 High PBX3 (pre-B-cell leukemia homeobox 3) expression was related with slower progression to CRPC (HR: 0.18, 95% CI: 0.081-0.42; P0.001). 77 PCa-related tumor suppressor genes are the same as oncogenes. On the one hand, their application value remains to be proved; on the other hand, they are more suitable for the combined use of multiple genes to score PCa, so as to guide the clinical evaluation of the malignant degree and prognosis of PCa.
Methylated biomarker
Currently, there are more and more studies that have reported the association between DNA methylation and the carcinogenesis and progression of PCa. Aberrant DNA methylation of cancer-related genes plays an important role to regulate various kinds of signal pathways. So hypermethylated genes seem to be potential biomarkers, which may help to distinguish aggressive PCa from PCa without obvious clinical symptoms.
ConfirmMDx is a kind of assay analyzing DNA methylation patterns of several key tumor suppressors, such as glutathione S-transferase pi 1 (GSTP1), Ras association (RalGDS/AF-6) domain family member 1 (RASSF1), and adenomatosis polyposis coli (APC). 9 Among them, GSTP1 participates in detoxification, RASSF1 regulates cell cycle, and APC participates in apoptosis, cell migration, and adhesion. 9 In addition, hypermethylation of PITX2 (the paired-like homeodomain transcription factor 2) and PITX3 (paired-like homeodomain transcription factor 3) were also powerful predictors for PCa patients, which might discriminate neoplastic and nonneoplastic prostate tissues (P0.001), and predict the risk of biochemical recurrence (HR: 2.56, 95% CI: 1.44-4.54; P=0.001). 78 Gevensleben et al evaluated the potential of hypermethylated PD-1 (programmed death 1) and PD-L1 (programmed death ligand 1) as biomarkers in PCa. First, DNA methylation of PD-1 and PD-L1 was of lower level in normal tissue compared to tumor tissue. Secondly, submit your manuscript | www.dovepress.com
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Song et al hypermethylated PD-L1 was related with biochemical recurrence (HR: 1.24, 95% CI: 1.08-1.43; P=0.002) in PCa. These results indicated that PD-L1 methylation might be a prognostic biomarker for the risk assessment of PCa patients. 79 Furthermore, the promoter methylation of CDO1 (cysteine dioxygenase 1), 80 GADD45a (growth arrest and DNA-damage-inducible, alpha), 81 SLC18A2, 73 and HIST1H4K (histone cluster 1, H4k) 82 was also evaluated as prognostic biomarkers for biochemical recurrence of PCa patients after RP. In 2015, Yao et al found six aberrant methylation sites located on the Y-chromosome in PCa tissues. Among them, the methylated site (cg05163709) could become a potential diagnostic biomarker with a high AUC (0.915). 83 Except for hypermethylation, hypomethylation of trefoil factor 3 (TFF3) promoter was studied as a PCa biomarker in 292 RP patients and another 498 PCa cases by quantitative methylation-specific PCR and DNA methylation arrays and RNA sequencing. 84 These results demonstrated that the hypomethylation of TFF3 promoter and its high expression were significant in PCa tissues compared to benign prostatic samples (P0.001). Moreover, the expression level of TFF3 was associated with high ERG (P0.001), high Gleason score (P0.001), tumor stage (P0.001), and PSA recurrence after RP (P=0.013). 84 Both hypermethylation and hypomethylation belong to epigenetics. They are mainly used to predict the possibility of biochemical recurrence of PCa patients, and to assess the susceptibility to PCa.
Discussion
We had summarized a variety of biomarkers for PCa. Except for the molecules mentioned above, aberrant lipid metabolism markers, involving cholesteryl esters, 85 sterol regulatory element-binding protein-1, and fatty acid synthase, 86 were associated with PCa stage and Gleason score, and might distinguish PCa from benign prostate tissues. The circulating autoantibodies against tumor-associated antigens could also assist serum PSA screening to discriminate PCa from benign patients. 87, 88 Single-nucleotide variant (SNV) 14 or copy number variations (CNV) 89 often led to the heterogeneity of PCa, which could be used as the characteristic of some subtype of PCa. Besides, thiosulfate 90 and miR-205 91 were reported not to be suitable as biomarkers for PCa.
In Alford's review, 12 commercially available biomarker assays were summarized, which provided urologists multifaceted information about PCa outcomes and therapeutic effects. 9 For example, SelectMDx might be used in post-DRE urine samples, involving distal-less homeobox 1, HOXC6 (homeobox C6), serum PSA level, PSA density, DRE score, age at diagnosis, and family history. 9 The oncotype DX assay measured the transcriptional levels of 17 genes by the quantitative reverse transcriptase-polymerase chain reaction, including 5 reference genes (ARF, ATP5E, CLTC, GPS1, PGK1) and 12 genes involved in the androgen pathway, cellular organization, proliferation, and stromal response. 9 Summarizing the experience of these commercially valuable kits, we found that PCa scoring combined with multiple biomarkers might be an effective method for future clinical use.
Another concern for researchers is the origin of biomarkers. Exosomes, CTCs, and cell-free-circulating-tumor DNA collected from PCa patients might be the promising source of biomarkers for evaluating PCa diagnosis and prognosis, and they could be candidate markers by themselves, such as CTC count and cell-free DNA integrity. Another advantage for these body fluid specimens is convenience and noninvasive. Among them, exosomes are vesicles that carry proteins, DNA, lipids, and metabolites, and 30-150 nm in diameter, which can come from either blood or body fluids, such as patient's urine.
In summary, a combination of multiple biomarkers should be a feasible and accurate way to assess PCa risk. In addition, a series of marker tests can provide more powerful guidance for medical decision based on the patients' different clinical and pathologic stages. Of course, a lot of laboratory and clinical experiments are still needed to achieve the goal.
Conclusion
In the review, we summarized the molecules found in recent several years, which had the potential to become biomarkers for the diagnosis and prognosis of PCa. Furthermore, we divided them into several categories, such as noncoding RNA, fusion gene, proto-oncogene, tumor suppressor gene, and gene methylation. Some of them had been applied in clinical practice, or were being developed to be used in the commercial reagent kits. However, most of the molecules were still in the laboratory research stage. More laboratory tests and clinical trials were needed.
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